Amgen Inc. (ETR: AMG)
Germany
· Delayed Price · Currency is EUR | Market Cap | 142.13B |
| Revenue (ttm) | 29.17B |
| Net Income (ttm) | 3.79B |
| Shares Out | n/a |
| EPS (ttm) | 7.02 |
| PE Ratio | 37.48 |
| Forward PE | n/a |
| Dividend | 8.35 (3.16%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 809 |
| Average Volume | 579 |
| Open | 263.50 |
| Previous Close | 262.15 |
| Day's Range | 258.00 - 267.00 |
| 52-Week Range | 243.30 - 318.05 |
| Beta | 0.60 |
| RSI | 55.22 |
| Earnings Date | Feb 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N... [Read more]
Financial Performance
In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.
Financial numbers in USD Financial StatementsNews
Amgen: Likely To Be Rangebound (Rating Downgrade)
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation
The Food and Drug Administration approved Amgen Inc ‘s (NASDAQ: AMGN) Lumakras (sotorasib) in combination with Vectibix (panitumumab) for KRAS G12C-mutated metastatic colorectal cancer (mCRC), who ha...
FDA Approves Amgen's LUMAKRAS and Vectibix Combination for Metastatic Colorectal Cancer
FDA Approves Amgen's LUMAKRAS and Vectibix Combination for Metastatic Colorectal Cancer
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today anno...
FDA Greenlights Amgen's New Cancer Drug Combo, Boosting Survival for KRAS G12C Patients
FDA Greenlights Amgen's New Cancer Drug Combo, Boosting Survival for KRAS G12C Patients
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Amgen Inc. (NASDAQ:AMGN) 43rd Annual J.P.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
S&P index moves into positive territory
The S&P index has moved into positive territory. The high price just reached 5830.76. The current price is trading at 5827.41 up 0.41 points on the day. The Dow industrial average is extending its gai...
Peering Into Amgen's Recent Short Interest
Amgen's (NYSE: AMGN) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 11.17 million shares sold short , which is 2.08% of all regular shares th...
3 "Dogs of the Dow" to Buy Now
The Dogs of the Dow are a favorite pet among income-minded investors, especially at the start of the new year. The term "Dogs of the Dow" is largely credited to money manager Michael B. O'Higgins. In ...
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P.
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinica...
UK Greenlights Amgen's Drug For Aggressive Lung Cancer In Pretreated Patients
On Monday, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) granted a conditional marketing authorization to Amgen Inc’s (NASDAQ: AMGN) Imdylltra for extensive-stage small cell l...
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)
Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold to buy.
Amgen: Growth Potential Met By High Debt Levels
Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Explore more details here.
Amgen's IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom
CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA® for...
Amgen: Blockbusters, Emerging Therapies, And Investment Potential
Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent expirat...
Big Blue Chip Dividends? Try These ‘Dogs' Up To 6.8%
The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
January Dow Dogs: 1 'Safer' Buy, And 5 With Promise
Verizon Communications is the only Dow Dog meeting the ideal of annual dividends from $1K invested, exceeding the single share price. Analysts forecast 11.36% to 31.73% net gains from the top ten Dow ...
Amgen stock price formed a death cross: will it rebound in 2025?
The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July, the stock plunged by over 25% to the current $260...